Targeting dendritic cells with antigen via dendritic cell-associated promoters

Cancer Gene Therapy

Volumn 19, Issue 5, 2012, Pages 303-311

  Moulin, V ^a   Morgan, M E ^a   Eleveld Trancikova, D ^a   Haanen, J B A G ^b   Wielders, E ^a   Looman, M W G ^a   Janssen, R A J ^a   Figdor, C G ^a   Jansen, B J H ^a   Adema, G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

DC specific promoter; dendritic cell; DNA vaccination; tattoo

Indexed keywords

CD209 ANTIGEN; DC STAMP PROTEIN; ENHANCED GREEN FLUORESCENT PROTEIN; GLYCOPROTEIN P 15095; LANGERIN; OVALBUMIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DNA SEQUENCE; DRUG SAFETY; ELECTROPORATION; EMBRYO; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISOLATION; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD11C; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY, ADOPTIVE; LECTINS, C-TYPE; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NIH 3T3 CELLS; PROMOTER REGIONS, GENETIC; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES; TRANSFECTION; VACCINES, DNA;

MURINAE;

EID: 84859898868     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.2     Document Type: Article

References (39)

1. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006; 311: 17-58. (Pubitemid 47413194)
2. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 1999; 189: 169-178.
3. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998; 188: 1075-1082. (Pubitemid 28443331)
4. Donnelly RF, Raj Singh TR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv 2010; 17:187-207.
5. Mahe B, Vogt A, Liard C, Duffy D, Abadie V, Bonduelle O et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol 2009; 129: 1156-1164.
6. Mir LM. Nucleic acids electrotransfer-based gene therapy (electrogenetherapy): past, current, and future. Mol Biotechnol 2009; 43: 167-176.
7. Prow TW, Chen X, Prow NA, Fernando GJ, Tan CS, Raphael AP et al. Nanopatchtargeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small (Weinheim an der Bergstrasse, Germany) 2010; 6: 1776-1784.
8. Singh TR, Garland MJ, Cassidy CM, Migalska K, Demir YK, Abdelghany S et al. Microporation techniques for enhanced delivery of therapeutic agents. Recent Pat Drug Deliv Formul 2010; 4: 1-17.
9. Vandermeulen G, Daugimont L, Richiardi H, Vanderhaeghen ML, Lecouturier N, Ucakar B et al. Effect of tape stripping and adjuvants on immune response after intradermal DNA electroporation. Pharm Res 2009; 26: 1745-1751.
10. Babiuk S, Baca-Estrada ME, Foldvari M, Baizer L, Stout R, Storms M et al. Needlefree topical electroporation improves gene expression from plasmids administered in porcine skin. Mol Ther 2003; 8: 992-998. (Pubitemid 38072312)
11. Bennett AM, Phillpotts RJ, Perkins SD, Jacobs SC, Williamson ED. Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan Equine Encephalitis virus. Vaccine 1999; 18: 588-596. (Pubitemid 29509841)
12. Dincer Z, Jones S, Haworth R. Preclinical safety assessment of a DNA vaccine using particle-mediated epidermal delivery in domestic pig, minipig and mouse. Exp Toxicol Pathol 2006; 57: 351-357. (Pubitemid 43903623)
13. Dresch C, Edelmann SL, Marconi P, Brocker T. Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo. J Immunol 2008; 181: 4495-4506.
14. Geusens B, Strobbe T, Bracke S, Dynoodt P, Sanders N, Gele MV et al. Lipidmediated gene delivery to the skin. Eur J Pharm Sci 2011; 43: 199-211.
15. Peachman KK, Rao M, Alving CR. Immunization with DNA through the skin. Methods (San Diego, Calif) 2003; 31: 232-242. (Pubitemid 37162796)
16. Steele KE, Stabler K, VanderZanden L. Cutaneous DNA vaccination against Ebola virus by particle bombardment: histopathology and alteration of CD3-positive dendritic epidermal cells. Vet Pathol 2001; 38: 203-215. (Pubitemid 32194860)
17. Sudowe S, Ludwig-Portugall I, Montermann E, Ross R, Reske-Kunz AB. Transcriptional targeting of dendritic cells in gene gun-mediated DNA immunization favors the induction of type 1 immune responses. Mol Ther 2003; 8: 567-575. (Pubitemid 37321685)
18. van den Berg JH, Nuijen B, Beijnen JH, Vincent A, van Tinteren H, Kluge J et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther 2009; 20: 181-189.
19. Bonkobara M, Zukas PK, Shikano S, Nakamura S, Cruz Jr PD, Ariizumi K. Epidermal Langerhans cell-targeted gene expression by a dectin-2 promoter. J Immunol 2001; 167: 6893-6900. (Pubitemid 33144182)
20. Ross R, Sudowe S, Beisner J, Ross XL, Ludwig-Portugall I, Steitz J et al. Transcriptional targeting of dendritic cells for gene therapy using the promoter of the cytoskeletal protein fascin. Gene Ther 2003; 10: 1035-1040. (Pubitemid 36722494)
21. Sudowe S, Ludwig-Portugall I, Montermann E, Ross R, Reske-Kunz AB. Prophylactic and therapeutic intervention in IgE responses by biolistic DNA vaccination primarily targeting dendritic cells. J Allergy Clin Immunol 2006; 117: 196-203. (Pubitemid 43017161)
22. Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000; 100: 575-585.
23. Hartgers FC, Vissers JL, Looman MW, van Zoelen C, Huffine C, Figdor CG et al. DCSTAMP, a novel multimembrane-spanning molecule preferentially expressed by dendritic cells. Eur J Immunol 2000; 30: 3585-3590. (Pubitemid 32005231)
24. Valladeau J, Duvert-Frances V, Pin JJ, Dezutter-Dambuyant C, Vincent C, Massacrier C et al. The monoclonal antibody DCGM4 recognizes Langerin, a protein specific of Langerhans cells, and is rapidly internalized from the cell surface. Eur J Immunol 1999; 29: 2695-2704. (Pubitemid 30098994)
25. Winzler C, Rovere P, Rescigno M, Granucci F, Penna G, Adorini L et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997; 185: 317-328. (Pubitemid 27078288)
26. Karttunen J, Sanderson S, Shastri N. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl AcadSci USA 1992; 89: 6020-6024.
27. Falo Jr LD, Kovacsovics-Bankowski M, Thompson K, Rock KL. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1995; 1: 649-653.
28. Casatorres J, Navarro JM, Blessing M, Jorcano JL. Analysis of the control of expression and tissue specificity of the keratin 5 gene, characteristic of basal keratinocytes. Fundamental role of an AP-1 element. J Biol Chem 1994; 269:20489-20496.
29. Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TN et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005; 11: 899-904. (Pubitemid 41161124)
30. Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol 1998; 10: 443-448. (Pubitemid 28564373)
31. van den Berg JH, Nujien B, Beijnen JH, Vincent A, van Tinteren H, Kluge J et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther 2009; 20: 181-189.
32. Schreurs MW, Eggert AA, de Boer AJ, Vissers JL, van Hall T, Offringa R et al. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 2000; 60: 6995-7001. (Pubitemid 32059175)
33. Lauterbach H, Gruber A, Ried C, Cheminay C, Brocker T. Insufficient APC capacities of dendritic cells in gene gun-mediated DNA vaccination. J Immunol 2006; 176:4600-4607.
34. Cho JH, Youn JW, Sung YC. Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. J Immunol 2001; 167: 5549-5557.
35. Bros M, Ross XL, Pautz A, Reske-Kunz AB, Ross R. The human fascin gene promoter is highly active in mature dendritic cells due to a stage-specific enhancer. J Immunol 2003; 171: 1825-1834. (Pubitemid 36966465)
36. Rea D, Havenga MJ, van Den Assem M, Sutmuller RP, Lemckert A, Hoeben RC et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 2001; 166: 5236-5244. (Pubitemid 32280740)
37. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001; 98: 10290-10295. (Pubitemid 32803013)
38. Pokorna D, Rubio I, Muller M. DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet Vaccines Ther 2008; 6: 4.
39. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000; 21: 163-165. (Pubitemid 30184783)